Prosthetic joint infection (PJI) is a complication of hip or knee replacement surgery, occurring in about 2% of all arthroplasties. The incidence of prosthesis implantations, and consequently the burden of PJI is rising rapidly. In the United States, there were about 1 million total hip and knee replacements performed in 2010 and this number is expected to reach 4 million by 2030. PJIs are extremely difficult to treat and often require surgical intervention due to the formation of bacterial biofilms. PJIs are devastating to patients and have significant economic impact to the healthcare system. The treatment of PJIs represents a major unmet medical need in infectious disease area.
TNP-2092 is a multi-targeting New Molecular Entity specifically designed for the treatment of infections associated with bacterial biofilms. The compound exhibits potent activity against major pathogens associated with PJIs, including those resistant to the available antibiotics, and shows low propensity for development of resistance. The compound demonstrats excellent activity in various in vitro and in vivo infection models associated with bacterial biofilms.